Outcomes in Patients with NSTE-ACS Undergoing PCI on a Novel Tissue Factor/factor VIIa Inhibitor (rNAPc2) with Full, Half-Dose or No Heparin in the ANTHEM-TIMI 32 Trial
Outcomes in Patients with NSTE-ACS Undergoing PCI on a Novel Tissue Factor/factor VIIa Inhibitor (rNAPc2) with Full, Half-Dose or No Heparin in the ANTHEM-TIMI 32 Trial. TCT. 2006.